Mabylon

Developer of therapeutics for allergies and neurodegenerative diseases

placeSchlieren, Zurich, Switzerland calendar_todayFounded 2015 language mabylon.com

Social engagement

Social engagement: 2.3K social following, 4 posts in the last 12 months — below the industry typical range.

Investor mix

5 investors on record.

Investor typeCountShare
Accelerator & incubator120%
Other / undisclosed480%

Recent activity

11 Dec 2025
Milestone
regulatory
Coming soon